ClinicalTrials.gg
RecruitingNCT07935616Updated Nov 13, 2026

Zileuton for Food Allergy

A Phase 1 interventional study of Zileuton extended release in Food Allergies, sponsored by Abigail Lang. Recruiting at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Abigail Lang · Phase 1, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Food Hypersensitivity with a site in United States — 20 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.

Planned enrollment
79th of 105
20 · median 41
Started
2026
with 5 others
Phase 1
18 of 139
1 open now
Primary completion
2027-12
later than 15 of 27 live
Registered
139th of 139
by date

Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 79th largest by planned enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 15 of the 27 other live ones, and was the 139th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 92 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

20 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 42 (78%) stop at 75 or younger; 46 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Food Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

Our proposed project will seek to determine if an oral medication called zileuton, which blocks the synthesis of inflammatory molecules called leukotrienes that are involved in allergic reactions, may be able to decrease absorption of food allergens and prevent severe food allergy reactions from occurring. Our study will measure levels of peanut in the blood before and after subjects consume an allergen they can tolerate and compare the results with and without administration of the study medication, zileuton. If our study shows that zileuton can decrease the absorption of a food allergen, this will allow us to see if this medication can be used to prevent anaphylaxis to food.

The goal of this proof-of-concept study is to determine whether zileuton inhibits food allergen absorption in children and adolescents with food allergy. The main questions it aims to answer are:

  • Does zileuton administration impact food allergen absorption in children and adolescents with food allergies?
  • What is the variability of food allergen absorption in children and adolescents with IgE-mediated food allergies?

Researchers will compare levels of peanut allergen proteins in the participants' blood with and without a dose of zileuton prior to a test meal of peanut protein.

  • Visit 1 will involve a baseline blood draw, a test meal of peanut protein and a post-meal blood draw.
  • Visit 2 will involve a baseline blood draw, a dose of zileuton before the test meal of peanut protein, and blood draws after the test meal.
03

Conditions studied

  • Food Allergies

Keywords

  • food allergies
  • zileuton
  • anaphylaxis
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescent subjects ages 12-17
  • Parent or guardian fluent in English
  • Known IgE-mediated food allergy other than peanut

    • Confirmed by clinical history of reaction to the food antigen plus

      1. positive skin prick testing and/or serum food-specific IgE AND
      2. confirmation of the food allergy diagnosis by a board-certified allergist

Exclusion criteria

Exclusion Criteria:

  • A previous positive peanut specific IgE test or skin prick test, or a history of any allergic symptoms following peanut consumption
  • Medical conditions known to affect the gastrointestinal tract
  • Any history of hepatic disease or previous abnormal liver function tests
  • Previous or anaphylaxis to zileuton
  • Current use of a medication known to interact with zileuton, such as theophylline, warfarin, or propranolol
  • History of drug or alcohol abuse
  • Use of any drugs within 30 days of screening
  • Initiation of allergen immunotherapy within 3 months prior to Visit 1 or a plan to begin therapy during the trial
  • Use of leukotriene antagonists/modifier such as montelukast
  • Pregnant persons
  • Individuals with uncontrolled neuropsychiatric disorders
  • Use of oral (OCS) within 2 weeks before screening or are scheduled to receive OCS during the study period for another condition
  • Monoclonal antibody or treatment within 3 months of screening
  • Past or current medical problems which in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or may compromise the quality of the data obtained from the study
  • Inability or unwillingness of a parent or guardian to give written or participant to give assent
  • Non-English speaking participants
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Study treatment

    Treatment with a single dose of Zileuton administered at Visit 2.

    Drug: Zileuton extended release

Interventions

  • Zileuton is available in 600 mg strength yellow-colored oval tablets. A single dose of 1200 mg zileuton ER (two 600 mg zileuton tablets) will be administered to each participant.

    Also known as: Zyflo

06

What researchers measure

Primary outcomes

  1. Inhibition of food allergy absorption by zileuton

    Comparison of serum peanut antigen levels pre- and post-peanut test meal will be performed in each participant for Visit 1 (baseline) and Visit 2 (with study drug) to determine absorption of peanut. Comparison of post-meal peanut levels with and without zileuton treatment in each participant will also be performed to see whether gut permeability to peanut changes with study drug administration.

    Time frame: 1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)

Secondary outcomes

  1. Variability in allergen absorption in children and adolescents with food allergy

    Comparison of peanut antigen levels between participants to assess any variability in absorption of food antigens between individuals.

    Time frame: 1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hoyt LR, Liu E, Olson EC, Jacobsen DR, Siniscalco ER, Krier-Burris RA, Greenfield KG, McBride CD, Alfajaro MM, Amat JAR, Zhao Z, Xu L, Philip V, Verma A, Fourati S, Senger DL, Zhang L, Bunyavanich S, Glass SE, Coffey RJ, Wilen CB, Williams A, Eisenbarth SC. Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice. Science. 2025 Aug 7;389(6760):eadp0240. doi: 10.1126/science.adp0240. Epub 2025 Aug 7. PubMed 40773557 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 13, 2026
StartEst.
Nov 3, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935616
Lead sponsor
Abigail Lang
Responsible party
Abigail Lang (Attending Physician, Assistant Professor of Pediatrics, Ann & Robert H Lurie Children's Hospital of Chicago) — Sponsor-investigator
First posted
Nov 13, 2026
Start date
Nov 3, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Abigail Lang, MD, MSCI
Contact
AllergyResearchNurse@luriechildrens.org
800-543-7362 ext. "0", 76474
Michelle Catalano, BS, LPN
Contact
MCatalano@luriechildrens.org
800-543-7362 ext. "0", 76455

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zileuton

Start the discussion